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A growing literature has highlighted important differences in
transplant-related outcomes between men and women. In the
United States there are fewer women thanmen on the liver trans-
plant waitlist and women are two times less likely to receive a
deceased or living-related liver transplant. Sex-based differences
exist not only in waitlist but also in post-transplant outcomes,
particularly in some speciﬁc liver diseases, such as hepatitis
C. In the era of individualized medicine, recognition of these
differences in the approach to pre and post-liver transplant care
may impact short and long-term outcomes.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver. Open access under CC BY-NC-ND license.Introduction
A growing literature has highlighted important differences in
transplant-related outcomes between men and women. In the
United States, there are fewer women than men on the liver
transplant (LT) waitlist (38% vs. 62%) [1], and women are two
times less likely to receive a deceased or living-related LT [2–4]
(Fig. 1). While the MELD-based allocation system has decreased
waitlist mortality by prioritizing the sickest patients awaiting
LT [5], sex-based disparities in waitlist outcomes (Fig. 2) have
not been overcome. Indications for transplant (Figs. 3 and 4)
and their respective disease course post-LT also vary by sex. This
review focuses on the current knowledge of transplant-relatedJournal of Hepatology 20
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gender-speciﬁc management of transplant patients.
Key Points
• Transplant indications, waitlist outcomes, and post-
transplant course vary by sex
• Waitlist outcomes (liver allocation and waitlist mortality)
remain worse in women in the post model for end-
stage liver disease (MELD) era, particularly at high
MELD scores. Inadequate renal function measures that
underestimate renal impairment in women, as well as
differences in physical stature contribute to, but do not
fully explain sex differences in waitlist outcomes
• Despite different methodologies for measuring specific
quality of life (QOL) indicators, the overall findings
indicate that women have lower QOL scores post-liver
transplantation (LT) compared to men
• While overall post-transplant graft and patient survival
do not seem to differ by sex, in some specific liver
diseases, particularly in hepatitis C, sex differences
are evident (more severe recurrent disease and lower
response rates to interferon-ribavirin based therapies in
women)
• Data on sex differences in alcohol recidivism rates are
conflicting
• Recipient sex does not appear to predict risk of
recurrent hepatocellular carcinoma (HCC) post-LTAge at transplant
Both men and women are most commonly transplanted between
50 and 64 years of age, though a somewhat higher percentage of
women are transplanted in the older and younger age ranges.
Among U.S. LT recipients in 2012, approximately 15% of women
were transplanted at >65 years of age compared to 13% of men,
and approximately 7% of women compared to 4% of men were
transplanted between ages 18 and 34 years [1].15 vol. 62 j 946–955
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Fig. 3. Indications for liver transplantation in 2013 in the US by sex. (A)
Indications for liver transplants in 2013 among U.S. women based on UNOS data.
(B) Indications for liver transplants in 2013 among U.S. men based on UNOS data.
ALD, alcohol liver disease; PBC, primary biliary cirrhosis; HCV, hepatitis C virus;
HCC, hepatocellular carcinoma; PSC, primary sclerosing cholangitis; AIH, auto-
immune hepatitis; HBV, hepatitis B virus; NAFLD, non-alcoholic fatty liver
disease.
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Fig. 1. Post-MELD era waitlist and transplant numbers by sex. (A) Post-MELD
era waitlist by sex. Number of women and men in the U.S. listed for liver
transplant based on data from the Scientiﬁc Registry of Transplant Recipients
(SRTR) in the post-MELD era. (B) Post-MELD era transplant numbers by sex.
Number of women and men receiving live and deceased donor liver transplants in
the U.S. based on SRTR data in the post-MELD era.
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Fig. 2. Post-MELD era waitlist mortality by sex. Number of deaths among
women and men in the U.S. based on SRTR data in the post-MELD era. Those
delisted as too sick for transplant are not included.
JOURNAL OF HEPATOLOGYTransplant rates and waitlist mortality
Women remain disadvantaged in the post-MELD era with worse
waitlist outcomes (Table 1) [6–9], with women 30% less likelyJournal of Hepatology 201than men to receive a transplant within 3 years of listing (OR
0.7; 95% CI 0.6–0.8; p <0.001) [9]. A recent US investigation of
trends in LT rates found that in the pre-MELD era, women had
a 9% lower adjusted transplant rate compared to men, which
increased to a 14% difference (p <0.004) after implementation of
MELD. The lower transplant rates among women compared to
men appeared to predominate at higher MELD scores with 20%
lower rates at MELD scores 20–29 and a 12% lower rate at MELD
scores of 30–40 (p values <0.05). However, similar transplant
rates were noted at MELD scores <15 [9]. Disparities in transplan-
tation rates may translate into higher healthcare expenditures for
waitlisted women, given the longer wait times and lower risk of
non-liver-related removal from the waitlist [9,10].
Recent data investigating the rate of waitlisting relative to
those potentially eligible for transplant, have found that women
may have greater access to the transplant waitlist, despite lower
rates of transplantation than men [9,11]. These data also high-
light an ongoing racial/ethnic disparity for Hispanics, who have
lower transplant rates compared to other racial/ethnic groups
in the post-MELD era, although sex-based disparities in trans-
plant rates by race/ethnicity have not speciﬁcally been identiﬁed
[11].5 vol. 62 j 946–955 947
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Fig. 4. Indications for liver transplantation in 2012 in Europe by sex. (A)
Indications for liver transplants in 2012 among European women based on ELTR
data. (B) Indications for liver transplants in 2012 among European men based on
ELTR data (data kindly provided by V. Karam).
ReviewWomen have also been shown to be at higher risk of death or
becoming too sick for LT (OR 1.3; 95% CI 1.1–1.5; p = 0.003) [7]
(Fig. 2). This higher risk of waitlist mortality in women has been
observed in most [12,13], but not all studies [9]. There are several
hypotheses to explain sex differences in waitlist outcomes. A
major focus has been on renal function measures. It has been pro-
posed that less muscle mass in women results in lower creatinine
levels for similar degrees of renal impairment than men, resulting
in overall lower MELD scores [14,15]. Though creatinine levels do
contribute to sex differences in waitlist outcomes, studies adjust-
ing for estimated glomerular ﬁltration rate (eGFR), and thereby
accounting for gender differences in renal function, reveal persis-
tent disparities in liver allocation and waitlist mortality [8,12,14].
In a study using iothalamate as a direct measure of GFR in wait-
listed patients, women were more likely than men to have a pre-
transplant GFR <60 ml/min (29% vs. 21%) and <30 ml/min (10% vs.
6%, respectively) [16]. A U.S.-based study in the post-MELD era
(n = 42,322) noted similar overall waitlist mortality, but among
patients with non-dialysis dependent End Stage Renal Disease
(ESRD), women were more likely to die on the waitlist than
men (26% vs. 20%; p = 0.001) [17]. Moreover, despite lower GFRTable 1. Key sex differences in waitlist outcomes in the post-MELD era.
Waitlist times and transplant rates • Women spend longer on waitlist [2
• Transplant rates are higher in men
Waitlist mortality • Many studies note higher mortality
Size • Patient height/liver volume contribute
Renal function • Waitlisted women have lower creat
• Creatinine and MELD scores inade
Sarcopenia • Sarcopenia is strongly associated w
• Women may have lower risk of sar
948 Journal of Hepatology 201levels, women were less likely to receive dialysis [18], and lower
rates of dual liver-kidney transplant were reported in women
compared to men with non-dialysis dependent ESRD (OR 0.5;
p <0.001) [19].
Another potential reason for the higher waitlist mortality
among women relates to physical stature. Deceased donors are
more often male, thus with size matching, more likely to be allo-
cated to men. In addition, preferential allocation of small or split
livers to children may also limit the pool of available organs for
women, contributing to longer waitlist times and higher risk
waitlist dropout [6]. A UNOS-based study found that women
had a 20% higher risk of death than men, after adjusting for
age, region, blood type, disease etiology, race, and MELD but this
difference largely disappeared with the addition of height to the
model (HR 1.04; 95% CI 0.98–1.1; p = 0.2) [13]. Another UNOS-
based study found that although women were 25% less likely to
undergo LT in a given month compared to men, this decreased
to 17% with adjustment for renal function, and to 13% with fur-
ther adjustment for liver volume [6]. These data suggest that like
renal function, physical stature contributes to, but does not fully
explain sex differences in waitlist outcomes.
Interestingly, while 35% of deceased-donor LT recipients are
women, 44% of live donor transplants are in female recipients.
The higher percentage of women receiving a live as compared
to deceased donor transplant may be reﬂective of their smaller
stature, and therefore better suitability for smaller, live donor
grafts [1].
The implications of these ﬁndings are several-fold. First, con-
tinued efforts to ﬁnd markers of renal function that are gender
independent are essential. Second, nephrologists need to consider
gender differences in their recommendations for renal replace-
ment therapy and kidney transplant. Third, women should be
encouraged to pursue living donation, and programs may need
to consider splitting more organs to offset the longer wait times
for women. Finally, continued evaluation of gender disparities as
the MELD system evolves is critical for affecting outcomes in
waitlisted women and informing future allocation policy.Post-transplant outcomes
Patient and graft survival
Whether there are sex differences in post-transplant survival,
remains controversial. A recent study from Germany (n = 266)
found that female sex in the post-MELD era was a strong and
independent risk factor for 90-day post LT mortality (OR 3.2;
95% CI 1.3–7.6; p = 0.009). Women had higher MELD scores at-4,7-9]
 [7-9]
 [7,12,13] in women, but not all [9]
 to sex disparity in transplant rates and waitlist mortality [6,13]
inine for similar degree of renal failure [8,12,14-16]
quately reflect renal dysfunction in women
ith waitlist mortality
copenia [35]
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transplant than men in this study, and higher post LT mortality
was only identiﬁed among individuals with pre-transplant MELD
scores >20 (33% vs. 14%; p <0.05), and not among those with
MELD scores <20 (10 vs. 4%; p >0.05) [20]. Recent data from the
U.S. Scientiﬁc Registry of Transplant Recipients (SRTR)
(n = 19,249) found higher donor risk indices in women than
men (1.46 vs. 1.4; p <0.001), with a 24% higher odds among
women receiving a low quality graft (OR 1.24; p <0.001). This is
possibly driven by use of smaller grafts allocated to women,
but with no difference in graft survival between women and
men after adjustment for differences in graft quality [21].
Donor gender has also been investigated as a factor inﬂuenc-
ing graft survival. Older studies report worse post-LT survival in
gender mismatched transplants, with particularly high risk of
graft loss noted in male recipients of female donors [22,23].
Recent data from Germany noting higher post-transplant mortal-
ity in women did not identify donor gender mismatch as a con-
tributing factor [20]. Other studies indicate that donor quality,
rather than donor gender or sex mismatch are more important
in predicting graft survival. In composite, it remains unclear to
what extent sex mismatch or receipt of a female donor, contrib-
ute to potential differential post-transplant outcomes.
Rejection
The immune proﬁle of men and women are distinct, with women
having been described as more ‘‘immunogenic’’ than men, with
greater antibody production and higher rates of autoimmune
conditions [24]. Sex differences in immune activity may also
translate into different post-transplant immunosuppression
needs. A recent multicenter trial investigating immunosuppres-
sion withdrawal after LT identiﬁed male sex as an independent
predictor of successful weaning and subsequent development of
immune tolerance (OR 4.7; p = 0.016) [25]. Interestingly, the
opposite may hold true in the pediatric population, and maternal
grafts in female recipients may also protect against rejection in
children with biliary atresia [26,27]. In the hepatitis C population,
female gender has been shown to predict early acute rejection
(HR 1.8; 95% CI 1.2–2.7; p = 0.004) [28]. Although older studies
suggest that female recipients of male livers may be predisposed
to chronic rejection, in studies that include all liver conditions no
deﬁnitive sex differences in risk of acute or chronic rejection have
been demonstrated [29–31].
Renal dysfunction
Female sex has been shown to be an independent risk factor for
post-transplant renal impairment [32–34] for similar reasons as
described above. While earlier studies have been limited by use
of indirect measures of renal function, a recent study using
iothalamate as a direct measure of GFR also identiﬁed female
sex as an independent predictor of Pstage 3 CKD at 1 (OR 3.0;
95% CI 1.7–5.1; p <0.001) and 5 years post-transplant (OR 2.5;
95% CI 1.3–4.7; p = 0.004). This ﬁnding appeared to be related
to worse renal function in women compared to men in the pre-
transplant setting [16].
Sarcopenia or physical condition
Recent data indicate that sarcopenia, or severe muscle depletion,
is strongly associated with waitlist mortality, but with men atJournal of Hepatology 201greater risk than women (OR 5.9; 2.4–14.6; p <0.001) [35].
Pre-transplant muscle mass is also emerging as an important pre-
dictor of post-transplant outcomes. A study of 338 transplant
candidates (223 men, 115 women) found that low muscle mass
as determined by CT scan was strongly associated with post-
transplant length of ICU stay, total length of hospital stay, and
number of days requiring intubation, although this effect was
modest in women and quite strong in men. In men, but not
women, low muscle mass was also associated with worse post
LT survival and hospital disposition [36,37]. The differential effect
may be related to greater baseline muscle mass in men for whom
a greater degree of cachexia and catabolism is reﬂected in the
presence of sarcopenia, though further investigation is required.
Quality of life
Data on sex differences in overall quality of life (QOL) after LT
have been conﬂicting [38]. Older studies found no differences
[39,40] whereas more recent data report lower QOL scores at 1
and 2 years in women compared to men [41], as well as worse
psychosocial adjustment in women [42]. In contrast, a small
study (n = 52) of patients transplanted for hepatitis C virus
(HCV) found that women had signiﬁcantly better mental health,
emotional role functioning, as well as lower pain scores than
men, whereas men felt they had better physical functionality
after LT [43]. A larger post LT cohort (n = 386) including all liver
diseases noted worse measures of physical distress and personal
function in women, without apparent sex differences in psycho-
logical distress or general health perception [44]. Despite differ-
ent methodologies for measuring speciﬁc QOL indictors, the
overall ﬁndings indicate that sex differences in post LT QOL are
apparent.
Cirrhosis is known to impair sexual function, an important
QOL measure. Most men and women experience improved sexual
function after LT [45], though one large study of 233 transplanted
women found no improvement in multiple measures of sexual
satisfaction following transplant [46]. De novo sexual dysfunction
following LT has been identiﬁed in 33% of men and 26% of women
(p value not reported) [47]. Persistent sexual dysfunction follow-
ing transplant may relate to depression, and psychosocial inter-
ventions in the post LT setting may be underutilized [48].
Interestingly, a recent study found that marital happiness was
not affected by LT in men, while women in the post LT setting
experienced marked improvement in conjugal satisfaction, which
correlated with sexual function in women (r = 0.4; p = 0.02), but
not in men (r = 0.1; p = 0.3) [45]. Chronic anovulation and symp-
toms of premature menopause are common problems in women
with end-stage liver disease and most pre-menopausal women
do have restoration of ovarian function and fertility after
transplant [49]. Pregnancy outcomes in the post-LT setting have
been well studied, though beyond the scope of the current review
[50–53].
Non-hepatic complications following liver transplantation
With increased life expectancy, de novo tumors and cardiovascu-
lar disease are now leading causes of non-graft related death in
long-term liver transplant survivors [54–56]. This high incidence
of non-hepatic events is theoretically explained by the presence
of pre-existing risk factors, as well as the introduction of addi-
tional risk factors associated with the organ transplant process,5 vol. 62 j 946–955 949
Table 2. Sex differences in overall post LT outcomes.
Outcome Sex difference Comment
Patient/graft survival Controversial German study identified higher 90-day mortality in women [20]. U.S. study did  
not identify sex difference [21]
Rejection risk No No overall sex difference in acute or chronic rejection [29-31] though higher risk of 
early acute rejection in women with HCV [28]. Women less likely to wean from IMS 
and develop immune tolerance [25]
Quality of life Yes Considerable variability in the definition of specific QOL indicators though 
differences in sexual function, emotional and physical well-being are apparent 
Renal function Yes Women at higher risk of CKD post LT [16,32-34]
Post LT recovery and sarcopenia Yes In men, but less so women, sarcopenia is associated with worse post LT survival 
and post operative recovery [36-37]
Reviewsuch as chronic exposure to immunosuppressive agents, life-style
habits (weight gain, tobacco use), and/or the development of de
novo metabolic disorders including post-transplant arterial
hypertension, diabetes and/or dyslipidemia. With respect to car-
diovascular risk factors and disease, no gender association has
been found in most studies to date [54,57]. Interestingly, the fact
that male gender is a known risk factor for malignancy in the
general population but not in post-transplant studies suggests
that women have closed the gap, and hence are at higher risk
than women in the general population.
Overall, the risk of malignancy is 2 to 4 times higher in
transplant recipients than in an age- and sex-matched population
[58–62]. With the exception of a few studies where men appear
to be more affected than women [62–65], there does not appear
to be a clear gender-based difference in the incidence of de novo
malignancy. Importantly, since the incidence rates of breast
cancer is not increased in organ transplant recipients, there is
no evidence to suggest the need for breast cancer screening that
would differ from the general population [54].Post-transplant outcomes in speciﬁc liver diseases (Table 2)
Chronic hepatitis C
Chronic hepatitis C is an important cause of cirrhosis and hepato-
cellular carcinoma (HCC) globally. In the United States, Europe
and Japan, HCV is the most common indication for LT. In recent
years, the proportion of patients with HCC as the primary indica-
tion for LT has increased, likely reﬂecting prioritization of small
HCC for LT as well as the increased prevalence of cirrhosis among
HCV-infected persons [66,67]. Cirrhosis and its complications are
less frequent in women than men [67] and this difference is likely
due to the higher rates of spontaneous clearance among women
[68], the protective effects of estrogens on ﬁbrosis in premeno-
pausal women [69], as well as lower frequency of cofactors
associated with ﬁbrosis in women, such as heavy alcohol use.
Recurrent disease is essentially universal among viremic
patients after LT and the estimated median time to recurrent cir-
rhosis is 8–10 years [70] with rapid progressors advancing to cir-
rhosis within 3–5 years [71]. Approximately 10% develop severe
early recurrence with cholestatic features within the ﬁrst year
post LT, which can rapidly progress to graft loss in the absence
of antiviral therapy. Higher rates of severe HCV disease and
reduced graft survival are associated with several recipient and950 Journal of Hepatology 201donor factors, including African-American race, HIV co-infection,
older donor age and IL28B polymorphisms. Women have more
severe recurrent disease [72–74] with a 23% higher risk of
advanced ﬁbrosis than men after a median of 3 years after liver
transplant [72]. Viral eradication prior to or after LT can prevent
complications of HCV recurrence. Few studies have focused on
sex differences in response to therapy, but the lower response
rates to interferon-based therapy in women [75] are likely due
to lower adherence to therapy and a higher rate of therapy dis-
continuation related to ribavirin-induced anemia. Sex differences
in treatment response with direct acting antiviral therapies have
not been studied, but the greater risk of ribavirin-associated tox-
icity may continue to limit therapy tolerability and efﬁcacy in
women (Table 3).
Non alcoholic fatty liver disease (NAFLD)
Non-alcoholic steatohepatitis (NASH) is the third most common
indication for LT in the United States and is predicted to surpass
HCV as the most common indication for LT in 10 years’ time [76].
Most population-based studies note a higher prevalence of
NAFLD in men, though clinically diagnosed and biopsy proven
NASH appears to be higher in women [77–79]. Hormonal factors
may contribute to this difference, as a recent cross sectional
study noted increased liver ﬁbrosis in men with NASH compared
to pre-menopausal women, but similar ﬁbrosis scores as post-
menopausal women [80]. Sex differences in NAFLD prevalence
may also equalize after women reach menopause [81,82].
Patients receiving LT for NASH are equally distributed by sex
[78], with no apparent sex differences in post LT patient or graft
survival [83,84], or risk of recurrent NASH [85,86].
Alcoholic liver disease (ALD)
There are clear sex differences in the hepatotoxic effects of alco-
hol, with higher risk of hepatic damage at lower doses of alcohol
exposure in women (>10 g daily) compared to men (>20 g daily)
[87]. This is in part related to lower levels of gastric alcohol dehy-
drogenase in women, which is involved in ﬁrst pass alcohol
metabolism [88]. Once diagnosed with ALD, women have more
rapid acceleration of liver ﬁbrosis than men, which may persist
even after alcohol cessation [89]. Consistent with this ﬁnding,
men on the waiting list for ALD tend to have longer median dura-
tions of alcohol abuse than women [90,91]. However, the overall
prevalence of ALD remains higher in men, and a greater5 vol. 62 j 946–955
Table 3. Sex differences in liver transplant by disease.
Liver disease Epidemiology Risk of cirrhosis/need for LT Post-LT outcome
HCV Less common in women 
[67] 
• Lower need for LT in women: related to
higher spontaneous clearance, lower
risk of fibrosis, and less concurrent
alcohol use [66-68]
• Fibrosis progression may be more
rapid in post- than pre-menopausal
women [69]
• Women at higher risk of graft loss [72-74]
• Possible lower risk of interferon response post LT
[75]
• No apparent difference in response to new direct
acting antivirals
•
•
Women at higher risk of early acute rejection [28]
NASH •
•
NAFLD more common
in men
• Biopsy proven NASH
higher in women
[77-79]
• Similar rates of fibrosis in men and pre-
menopausal women [81-82]. Fibrosis
progression may be more rapid in post- 
than pre-menopausal women [80]
• Similar transplant rates [78]
Similar rates of recurrent disease, patient, and 
graft survival [83-86]
ALD •
•
Less common in
women [90,92,93]
• Women at higher risk of cirrhosis with
lower doses of alcohol exposure [87]
• Men account for 75% of transplants for
ALD [78]
• Similar patient and graft survival [91-94]
• Recidivism controversial: may be higher in
women [95-96]
AIH More common in 
women, sex ratio 3.6:1 
[97]
• Controversial: male sex predictive of
death or need for LT [98-99]
• Women with AIH at lower risk for HCC [98]
• Similar post LT survival, recurrent AIH, and risk
of rejection [101-103]
PBC • 90% diagnosed in
women [104]
• Women more responsive to ursodiol [108]
• Women have less progressive disease
[101,106,107]
• Women with PBC at lower risk for HCC
[109-112]
• Similar risk of recurrent PBC and rejection [101,113]
• Limited data on post LT survival differences
PSC • 60% diagnosed in
men [114]
• Controversial: Most studies show no
difference in transplant-free survival
[115,116]
• One study found female sex predictive of
death or need for liver transplant [117]
• Similar risk of recurrent PSC [120-122] and
rejection [101]
• Limited data on post LT survival differences
JOURNAL OF HEPATOLOGYproportion of men undergo LT for ALD [90,92,93]. UNOS-based
data from 2002 to 2012 indicate that men account for 75% of
patients transplanted for a primary diagnosis of ALD [78].
Most studies have not identiﬁed sex differences in post LT
graft or patient survival for ALD [91,93], though one older study
noted a higher percentage of women than men surviving at
5 years (78% vs. 58%, respectively, no p-value provided) [94]. A
French study identiﬁed de novo malignancies as an independent
risk factor for lower post LT survival in ALD and though sex
was not predictive on multivariate analysis, male sex was
strongly associated with the risk of de novo malignancy [93].
Data on sex differences in recidivism rates are conﬂicting. A
Scandinavian study (n = 103) found no association between sex
and recidivism [95], while a Canadian study (n = 80) noted higher
recidivism in women, accounting for 5/8 patients that resumed
problem drinking. Interestingly, 4/5 of these women had a pre-
transplant diagnosis of depression, which may contribute to the
higher observed recidivism in women [96]. A U.S.-based study
has since reported depression to be a strong predictor of post
LT recidivism, though sex was not speciﬁcally investigated in this
model [90].
Autoimmune hepatitis (AIH)
Like most autoimmune conditions, AIH is more prevalent in
women than men, with a sex ratio of 3.6:1 [97]. Women comprise
the majority of patients that receive LT for AIH, though a recent
study (n = 1318) identiﬁed male sex as an independent predictor
of mortality or need for LT (HR 1.5 compared to women, 95% CIJournal of Hepatology 2011.2–2.2; no p-value reported). In this study, cirrhotic women with
AIH also had a lower HCC incidence rate per 1000 person-years
compared to men (0.6 vs. 5.5) [98]. A smaller study (n = 138)
noted a higher unadjusted risk of cirrhosis at the time of AIH
diagnosis in men than women (OR 2.8; 95% CI 1.2–6.2; p = 0.01)
though risk of mortality or need for LT was not different [99].
Interestingly, there are no apparent recipient sex differences in
risk of de novo autoimmune hepatitis (HR 0.8; 95% CI 0.3–2.3;
p = 0.7), although the risk of de novo AIH appears to be higher
in recipients of female donors regardless of recipient sex (HR
3.0; 95% CI 1.1–8.3; p = 0.03) [100]. To date, sex differences in risk
of post LT survival, recurrent AIH, or risk of rejection have not
been identiﬁed [101–103].
Primary biliary cirrhosis (PBC)
Like AIH, PBC is more common in women accounting for 90% of
PBC cases [104]. Women with PBC tend to be younger at the time
of diagnosis, with worse fatigue and pruritus than men, and
higher risk for concomitant autoimmune conditions. Interest-
ingly, recent data note similar fatigue and cognitive symptoms
in women after LT compared to sex matched non-transplant con-
trols (p values >0.05), whereas transplanted men compared to
non-transplant controls had worse fatigue (p <0.05) and cognitive
symptoms (p <0.005) [105]. Pre-LT serologic proﬁles are similar
in men and women, though men have more progressive disease
and overall worse outcomes [101,106,107]. A recent large study
(n = 2,353) found that men were less responsive to ursodeoxy-
cholic acid, based on ALT, total bilirubin and alkaline phosphatase5 vol. 62 j 946–955 951
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levels (OR 0.9; 95% CI 0.83–0.97; p = 0.007) [108]. Similar to most
chronic liver diseases, the incidence of HCC in PBC patients with
cirrhosis is lower in women than men, with a recent study noting
a 10-year HCC incidence of 2.0% in women vs. 6.5% in men
(p <0.001) [109–112]. Though HCC in women is predominantly
seen in cirrhosis, men with PBC have been diagnosed with HCC
at all stages of ﬁbrosis [112]. Data are limited on post LT sex dif-
ferences in patient or graft survival, though recurrent PBC or risk
of rejection appears to be similar between sexes [101,113].
Primary sclerosing cholangitis (PSC)
Unlike PBC and AIH, PSC is less common in women, with more
than 60% of cases diagnosed in men, and no major differences
in clinical presentation [114]. While most studies have not iden-
tiﬁed a difference in overall survival [115,116] a regional study
from Sweden (142 men and 57 women) identiﬁed female sex
as a strong and independent risk factor for death or need for LT
(RR 2.0; 95% CI 1.1–3.7; p = 0.02) [117]. The reasons for the dis-
crepancy in survival outcomes between this and other studies
are not clear, but may be related to delayed diagnosis in women
as this condition is more typically associated with men. Sex dif-
ferences in genetic factors contributing to PSC-related outcomes
have been identiﬁed. The rs738409 variant (I148M) of the PNPLA3
gene was recently shown to predict survival in patients with PSC
with concurrent dominant strictures, although this effect was
restricted to men (mean survival 11.9 years in I148M carriers
vs. 18.8 years in wildtype; p <0.001), and did not predict survival
in women (p = 0.65) [118].
Data reporting sex differences in post LT outcomes in PSC are
limited. A single center study (n = 83) noted a smaller proportion
of women than men with post LT biliary complications, revisions
of the transplanted liver, and/or death (32% vs. 65%, p = 0.02)
[119]. To date, no studies have demonstrated differences in risk
for recurrent PSC on adjusted analyses [120–122] or differences
in risk of rejection [101]. A study of 61 women and 119 men fol-
lowing LT for PSC identiﬁed a higher incidence of de novo colorec-
tal cancer in women (SIR 17.6; 95% CI 3.6–51.4) [123], though
other studies have not identiﬁed sex differences in risk of post
LT malignancy for patients with PSC [124,125].
Hepatocellular carcinoma
The risk ratio of HCC in cirrhotic women vs. men ranges from 1:2
to 1:4 [126]. Sex differences in HCC risk also extend to chronic
non-cirrhotic HBV infection for which the AASLD recommends
initiation of HCC screening in non-cirrhotic Asian women at age
50 years compared to 40 years in Asian men [127]. A large Italian
study (482 women and 1352 men) investigating all etiologies of
liver disease found that women were older at HCC diagnosis,
had higher alpha-fetoprotein levels, and were more likely to have
smaller, unifocal and well-differentiated HCCs, with lower likeli-
hood of presenting with metastases. Though overall survival was
better in women than men, there were no differences in likeli-
hood of undergoing curative treatment such as transplant or
resection. In this study survival differences disappeared when
subgroup analyses were performed among individuals diagnosed
with HCC by surveillance imaging opposed to symptomatic pre-
sentation, suggesting that sex differences in presentation and
outcomes may have been related to differential receipt of HCC
surveillance, rather than sex differences in tumor biology [128].952 Journal of Hepatology 201In a recent study from the U.S. Surveillance, Epidemiology, and
End Results database, women with HCC were found to have a sig-
niﬁcantly greater median overall survival compared with men,
independent of age, race, disease stage, or treatment (11 vs.
10 months; HR 0.93; 95% CI, 0.91–0.96, p <0.001). Interestingly,
greater survival in women was noted among those who received
surgical resection (HR 0.87; 95% CI 0.78–0.96; p = 0.01) but not
among those receiving liver-directed therapy or LT [129]. In
another U.S.-based study women were more likely to receive
curative resection than men. Though adjusted analyses revealed
lower risk of decompensation in women than men (OR 0.79;
p <0.001), these authors found that among those with compen-
sated cirrhosis and HCC, women were still more likely to be
offered curative therapy. No differences in rates of LT were noted
for patients with HCC, similar to previously reported UNOS data
[7,130]. In the latter study, tumor characteristics were not avail-
able, therefore higher rates of resection in women may be related
to lower tumor burden, as demonstrated in the Italian study
[128]. Recipient sex does not appear to predict risk of recurrent
HCC post LT [131–133].Acute liver failure
A high female predominance is observed in acute liver failure of
most etiologies, not only those associated with autoimmunity,
though the reason for this association is not clear. In particular,
acute liver failure due to Wilson disease occurs predominantly
in young females with a female to male ratio of 4:1. Furthermore,
approximately 10% of patients with hepatotoxicity due to medi-
cal/recreational drugs or herbal products may progress to fulmin-
ant hepatic failure, potentially requiring LT. While sex does not
seem to increase the overall risk of drug-induced liver injury,
the severity may differ by sex, with a predominance of severe
cases observed in women [134–136].Conclusions
LT remains the optimal treatment for patients with end-stage
liver disease, though sex differences in access to transplant per-
sist. In this review, we highlight sex-based disparities in trans-
plant outcomes, as well as sex differences in transplant
indications, some of which are quite marked and others more
subtle. Despite clear differences in waitlist outcomes, the reasons
for this particular disparity remain only partially understood.
Further data are clearly needed to narrow the gender gap in
transplant-related events, and to facilitate interventions that
may optimize the management of women in both the pre- and
post-transplant period.Financial support
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